Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 4, 2011, Pages 525-532

  Fujiwara, Toshiyoshi ^a   Shirakawa, Yasuhiro ^a   Kagawa, Shunsuke ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

adenovirus; colorectal cancer; lymph node; metastasis; telomerase

Indexed keywords

ADENOVIRUS VECTOR; CG 780; GREEN FLUORESCENT PROTEIN; OBP 301; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; TELOMELYSIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESCAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CHILL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISSEMINATED CANCER; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; FEVER; GENE ACTIVATION; GENE EXPRESSION; HUMAN; IN VIVO STUDY; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPH NODE METASTASIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PREOPERATIVE CARE; SINGLE DRUG DOSE; STOMACH CANCER; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; GASTROINTESTINAL NEOPLASMS; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TELOMERASE;

EID: 79955104230     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.200     Document Type: Article

References (68)

1. Kaplan JM. Adenovirus-based cancer gene therapy. Curr. Gene Ther. 5(6), 595-605 (2005). (Pubitemid 43009504)
2. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785(2), 217-231 (2008).
3. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9(1), 64-71 (2009).
4. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 9(17), 2577-2583 (1998). (Pubitemid 29004630)
5. Stone D, Lieber A. New serotypes of adenoviral vectors. Curr. Opin. Mol. Ther. 8(5), 423-431 (2006). (Pubitemid 44566783)
6. Wilson JM, Engelhardt JF, Grossman M et al. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a Phase I trial. Hum. Gene Ther. 5(4), 501-519 (1994).
7. Crystal RG, McElvaney NG, Rosenfeld MA et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8(1), 42-51 (1994).
8. Crystal RG, Hirschowitz E, Lieberman M et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8(8), 985-1001 (1997). (Pubitemid 27270161)
9. Sterman DH, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a Phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9(7), 1083-1092 (1998). (Pubitemid 28236516)
10. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4(2), 101-117 (2007). (Pubitemid 46189539)
11. Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma. Expert Opin. Biol. Ther. 9(3), 321-329 (2009).
12. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol. 3(1), 17-26 (2002). (Pubitemid 34121142)
13. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274(5286), 373-376 (1996). (Pubitemid 26353341)
14. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6(8), 879-885 (2000). (Pubitemid 30644745)
15. Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19(2), 289-298 (2001). (Pubitemid 32112839)
16. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72(12), 9479-9490 (1998). (Pubitemid 28520811)
17. O'shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6(6), 611-623 (2004). (Pubitemid 40017704)
18. Maehara Y, Oshiro T, Endo K et al. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 119(4), 397-402 (1996). (Pubitemid 26115831)
19. Rivadeneira DE, Simmons RM, Christos PJ et al. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J. Am. Coll. Surg. 191(1), 1-6 (2000).
20. Chang GJ, Rodriguez-Bigas MA, Skibber JM et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J. Natl Cancer Inst. 99(6), 433-441 (2007). (Pubitemid 47073566)
21. Volpe CM, Koo J, Miloro SM et al. The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma. J. Am. Coll. Surg. 181(1), 56-64 (1995).
22. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. J. Gastrointest. Surg. 2(2), 126-131 (1998). (Pubitemid 128432022)
23. Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med. 359(5), 453-462 (2008).
24. Gotoda T, Sasako M, Ono H et al. Evaluation of the necessity for gastrectomy with lymph node dissection for patients with submucosal invasive gastric cancer. Br. J. Surg. 88(3), 444-449 (2001). (Pubitemid 32238711)
25. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33(5), 787-791 (1997).
26. Dong CK, Masutomi K, Hahn WC. Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol. 54(2), 85-93 (2005).
27. Hiyama K, Hirai Y, Kyoizumi S et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155(8), 3711-3715 (1995).
28. Tahara H, Yasui W, Tahara E et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18(8), 1561-1567 (1999). (Pubitemid 29108056)
29. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2(4), 257-265 (2002). (Pubitemid 41043959)
30. Feng J, Funk WD, Wang SS et al. The RNA component of human telomerase. Science 269(5228), 1236-1241 (1995).
31. Harrington L, McPhail T, Mar V et al. A mammalian telomerase-associated protein. Science 275(5302), 973-977 (1997). (Pubitemid 27087712)
32. Meyerson M, Counter CM, Eaton EN et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90(4), 785-795 (1997). (Pubitemid 27357969)
33. Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277(5328), 955-959 (1997). (Pubitemid 27366681)
34. Nakayama J, Tahara H, Tahara E et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18(1), 65-68 (1998). (Pubitemid 28027882)
35. Beattie TL, Zhou W, Robinson MO et al. Reconstitution of human telomerase activity in vitro. Curr. Biol. 8(3), 177-180 (1998). (Pubitemid 28091578)
36. Keith WN, Sarvesvaran J, Downey M. Analysis of telomerase RNA gene expression by in situ hybridization. Methods Mol. Biol. 19165-19181 (2002).
37. Bilsland AE, Merron A, Vassaux G et al. Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res. 67(3), 1299-1307 (2007).
38. Wirth T, Zender L, Schulte B et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63(12), 3181-3188 (2003). (Pubitemid 36735870)
39. Lanson NA Jr, Friedlander PL, Schwarzenberger P et al. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 63(22), 7936-7941 (2003). (Pubitemid 37466730)
40. Irving J, Wang Z, Powell S et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 11(3), 174-185 (2004). (Pubitemid 38280520)
41. Kim E, Kim JH, Shin HY et al. Ad-mTERT-d19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 14(15), 1415-1428 (2003). (Pubitemid 37268220)
42. Huang TG, Savontaus MJ, Shinozaki K et al. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 10(15), 1241-1247 (2003). (Pubitemid 36934726)
43. Zou W, Luo C, Zhang Z et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23(2), 457-464 (2004). (Pubitemid 38175000)
44. Kuppuswamy M, Spencer JF, Doronin K et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther. 12(22), 1608-1617 (2005). (Pubitemid 41670351)
45. Li Y, Yu DC, Chen Y et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 61(17), 6428-6436 (2001). (Pubitemid 32783248)
46. Kawashima T, Kagawa S, Kobayashi N et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin. Cancer Res. 10(1 Pt 1), 285-292 (2004). (Pubitemid 38114191)
47. Taki M, Kagawa S, Nishizaki M et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin- RGD').Oncogene 24(19), 3130-3140 (2005). (Pubitemid 40695082)
48. Hashimoto Y, Watanabe Y, Shirakiya Y et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci. 99(2), 385-390 (2008). (Pubitemid 351228496)
49. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the promoter. Curr. Cancer Drug Targets 7(2), 191-201 (2007). (Pubitemid 46348634)
50. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 67(2), 429-432 (2007). (Pubitemid 46192175)
51. Burton JB, Johnson M, Sato M et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat. Med. 14(8), 882-888 (2008).
52. Kishimoto H, Kojima T, Watanabe Y et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat. Med. 12(10), 1213-1219 (2006). (Pubitemid 44527360)
53. Kurihara Y, Watanabe Y, Onimatsu H et al. Telomerase-specific virotheranostics for human head and neck cancer. Clin. Cancer Res. 15(7), 2335-2343 (2009).
54. Kojima T, Watanabe Y, Hashimoto Y et al. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann. Surg. 251(6), 1079-1086 (2010).
55. Kawabata K, Sakurai F, Koizumi N et al. Adenovirus vector-mediated gene transfer into stem cells. Mol. Pharm. 3(2), 95-103 (2006). (Pubitemid 43672245)
56. Burdelya LG, Krivokrysenko VI, Tallant TC et al. An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320(5873), 226-230 (2008). (Pubitemid 351521417)
57. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16), 15-18 (2002).
58. Fujiwara T, Tanaka N, Numunaitis JJ et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: evaluation of biodistribution and immune response. J. Clin. Oncol. 26(155), 3572 (2008).
59. Nemunaitis J, Tong AW, Nemunaitis M et al. A Phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin), for various solid tumors. Mol. Ther. 18(2), 429-434 (2010).
60. DeWeese TL, van der Poel H, Li S et al. A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61(20), 7464-7472 (2001). (Pubitemid 32995035)
61. Small EJ, Carducci MA, Burke JM et al. A Phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14(1), 107-117 (2006). (Pubitemid 43899483)
62. Yokoyama T, Iwado E, Kondo Y et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther. 15(17), 1233-1239 (2008).
63. Okada N, Tsukada Y, Nakagawa S et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun. 282(1), 173-179 (2001). (Pubitemid 32924361)
64. Fujiwara T, Kagawa S, Kishimoto H et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int. J. Cancer 119(2), 432-440 (2006).
65. Watanabe T, Hioki M, Fujiwara T et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res. 312(3), 256-265 (2006). (Pubitemid 41814835)
66. Liu D, Kojima T, Ouchi M et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol. Cancer Ther. 8(4), 980-987 (2009).
67. Fujiwara T, Tanaka N, Kanazawa S et al. Multicenter Phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 24(11), 1689-1699 (2006). (Pubitemid 46622140)
68. Sakai R, Kagawa S, Yamasaki Y et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol. Cancer Ther. 9(6), 1884-1893 (2010).